Pharmaceutical News

RSS

Neighboring non-cancer cells may contribute to drug resistance

One of cancer's most frightening characteristics is its ability to return after treatment. In the case of many forms of cancer, including the skin cancer known as melanoma, tailored drugs can eradicate cancer cells in the lab, but often produce only partial, temporary responses in patients. One of the burning questions in the field of cancer research has been and remains: how does cancer evade drug treatment?

5 Jul 2012

Cancer Therapeutics reveals proof of concept for second development drug

Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced the validation and performance of a new targeted drug, CTx-294886, in combination with Avastin™ (bevacizumab – Genentech/Roche) in a preclinical model of breast cancer. At the same time the Company announced that it has developed a new High Throughput Screening (HTS) platform for the identification of small molecule inhibitors of protein ubiquitination, a key element in the essential cellular process of protein homeostasis, which is an exciting new target pathway for cancer treatment. Both scientific developments will be presented as posters at the EACR conference in Barcelona Spain on July 7-10 2012.

4 Jul 2012

New research approach can help predict the 'tenability' of antibiotics

Research by Wageningen University, part of Wageningen UR, has shown that the development of bacteria with resistance against the antibiotic cefotaxime occurs more often and more predictably than was previously assumed. Bacterial populations were found to have many mutations that increase resistance and therefore have a negative effect on public health.

4 Jul 2012

GlaxoSmithKline agrees to plead guilty, pay $3B settlement

Drugmaker GlaxoSmithKline has agreed to plead guilty to fraud charges and pay $3 billion in total -- with some money going to nearly every state -- for promoting its bestselling antidepressants such as Paxil and Wellbutrin for unapproved uses, failing to report safety data about a top diabetes drug and improperly marketing other drugs.

4 Jul 2012

Antidepressant use among seniors: Falling through Medicare's doughnut hole?

A new study links the gap in Medicare Part D coverage and cutbacks by seniors in using this and other medications.

4 Jul 2012

Johnson & Johnson seeking U.S. approval for first new TB drug in more than 4 decades

"Johnson & Johnson [J&J] said Monday that it is seeking U.S. approval for the first new type of medicine to fight deadly tuberculosis [TB] in more than four decades," the Associated Press reports, adding, "The experimental drug, called bedaquiline, also would be the first medicine specifically for treating multi-drug resistant tuberculosis."

4 Jul 2012

Raising vitamin D concentrations reduces risk of HAIs among hospital patients

A paper recently published in Dermato-Endocrinology indicates that raising vitamin D concentrations among hospital patients has the potential to greatly reduce the risk of hospital-acquired infections.

4 Jul 2012

Tolfenamic acid appears to reduce esophageal tumors

A new study by researchers at MD Anderson Cancer Center Orlando finds that Tolfenamic acid (TA), a non-steroidal anti-inflammatory drug (NSAID), commonly used to relieve pain, inflammation and migraines has now been found to reduce esophageal tumors.

4 Jul 2012

Cuban company's sales of larvicides to fight malaria-carrying mosquitoes in Africa continue despite U.N. concern, Miami Herald reports

The Cuban state-owned company Labiofam "is increasing sales of its mosquito larvicides to fight malaria in Africa, despite cautions by U.N. experts that such products have limited use and are not the most cost-effective method of attacking the disease," the Miami Herald reports.

4 Jul 2012

FDA approves Lupin’s Norgestimate and Ethinyl Estradiol Tablets

Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. has received approval for its Norgestimate and Ethinyl Estradiol Tablets, 0.18 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.25 mg/0.025 mg from the United States Food and Drugs Administration (FDA).

4 Jul 2012

Researchers use mouse model of autism to treat CTD

Using a mouse model of autism, researchers at the University of Cincinnati (UC) and Cincinnati Children's Hospital Medical Center have successfully treated an autism spectrum disorder characterized by severe cognitive impairment.

3 Jul 2012

IRIN examines antibiotic resistance, efforts to discover new drugs

IRIN examines a global increase in resistance to antibiotics, writing, "Almost one in every five deaths worldwide occurs as a result of infection, but many bacterial illnesses will become incurable as the efficacy of current antibiotic drugs wanes, according to the World Health Organization (WHO)."

3 Jul 2012

Study shows link between changing rates of antibiotic consumption and resistance

A new study published in Clinical Infectious Diseases and available online shows how seasonal changes in outpatient antibiotic use - retail sales of antibiotics typically get a boost during the winter - can significantly alter seasonal patterns of drug resistance. The findings suggest that hospital campaigns to reduce inappropriate antibiotic use should be coordinated with efforts in the broader community if they are to be most effective.

3 Jul 2012

GRP78 plays an important role in breast cancers that respond to anti-estrogen therapy

Researchers at Georgetown Lombardi Comprehensive Cancer Center have uncovered a single molecule they say is a major determinant of resistance to anti-estrogen therapy used to treat or prevent breast cancer in high-risk women.

3 Jul 2012

GHB binds to GABAA-receptor in the brain under physiologically relevant conditions

Researchers are closer to understanding the biology behind GHB, a transmitter substance in the brain, best known in its synthetic form as the illegal drug fantasy. These findings have just been published in the scientific journal PNAS.

3 Jul 2012

$Researchers report positive effects of ibuprofen on bone repair after fracture or surgery$

Researchers report positive effects of ibuprofen on bone repair after fracture or surgery

A study conducted at the University of Granada has demonstrated that ibuprofen -a non-steroidal anti-inflammatory drug (NSAID)- has beneficial effects on bone repair after a fracture or following bone surgery.

3 Jul 2012

FDA accepts BLA filing and grants Priority Review to ThromboGenics' ocriplasmin

ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that it has officially accepted the filing of the Biologics License Application for ocriplasmin intravitreal injection, 2.5 mg/ml and granted it Priority Review.

3 Jul 2012

Pharmaceutical News

Neighboring non-cancer cells may contribute to drug resistance

Cancer Therapeutics reveals proof of concept for second development drug

New research approach can help predict the 'tenability' of antibiotics

GlaxoSmithKline agrees to plead guilty, pay $3B settlement

Antidepressant use among seniors: Falling through Medicare's doughnut hole?

Johnson & Johnson seeking U.S. approval for first new TB drug in more than 4 decades

Raising vitamin D concentrations reduces risk of HAIs among hospital patients

Tolfenamic acid appears to reduce esophageal tumors

Cuban company's sales of larvicides to fight malaria-carrying mosquitoes in Africa continue despite U.N. concern, Miami Herald reports

FDA approves Lupin’s Norgestimate and Ethinyl Estradiol Tablets

Researchers use mouse model of autism to treat CTD

IRIN examines antibiotic resistance, efforts to discover new drugs

Study shows link between changing rates of antibiotic consumption and resistance

GRP78 plays an important role in breast cancers that respond to anti-estrogen therapy

GHB binds to GABAA-receptor in the brain under physiologically relevant conditions

Researchers report positive effects of ibuprofen on bone repair after fracture or surgery

FDA accepts BLA filing and grants Priority Review to ThromboGenics' ocriplasmin

Study provides evidence for meth abuse's causal effect on foster home admissions

Study demonstrates effectiveness of combination therapy for breast cancer cells in vitro

Researchers show how aggressive form of multiple myeloma resists chemotherapy

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News